Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 10/20 | 0.74 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | AOC1 | P19801 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26117247 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL30608416 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL1686982 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL1534272 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL14028918 | 0.85 | HTR2B (0.54) | HTR2BGPR35AOC1 | |
| Pulicatins G SCHEMBL12469063 | 0.85 | HTR2B (1.00) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL3993242 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL3993320 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3AHTR2C | |
| SCHEMBL14028915 | 0.85 | HTR2B (0.54) | HTR2BGPR35AOC1 | |
| SCHEMBL11050644 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20080255081-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | HTR2B 4705/4885HTR1D 4829/4885HTR7 4873/4885 |
| US-20080255081-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | TXNRD2, PRDX3, SOD1 | HTR2B 3949/4885HTR1D 4346/4885HTR7 4393/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | HTR2B 4705/4885HTR1D 4829/4885HTR7 4873/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | HTR2B 4771/4885HTR1D 4858/4885HTR7 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.